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Abstract 
Hypertensive disorders (HDs) as the most prevalent medical problem during pregnancy, predispose the patient to a 
lot of comorbidities and may even cause maternal or fetal death. The rate of infertility has been increasing in recent 
decades. So, we collected and summarized data about the co-existence of these two entities and found that HDs are 
somewhat more common in women receiving fertility treatments regardless of pathophysiologic correlation of infer-
tility and hypertension or older age and chance of multiple pregnancies.
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Introduction 
Hypertensive disorders (HDs) are the most prevalent 
medical problem during pregnancy. It is estimated that 
HDs involve up to 6-8% of all pregnancies (1). HDs ac-
count for about 25% of all pre-birth hospital admissions 
(2). It has been well-documented that hypertension plays 
an important role in development of atherosclerosis conse-
quently leading to nonfatal or fatal myocardial infarction 
and cerebrovascular accidents. It has also been shown that 
hypertension is the main cause of perinatal and maternal 
morbidity and mortality including intrauterine growth re-
tardation (IUGR),  Hemolysis, Elevated Liver enzymes, 
and Low Platelet count (HELLP) Syndrome, renal im-
pairment, premature labor, neonatal intensive-care-unit 
admission, caesarean section, placental abruption, perina-
tal death and  maternal convulsion (3-5).
In a recent retrospective study done in Ethiopia, Seyom 
et al. (6) reported rate of dead fetus, low birth weight and 
low APGAR score,  abortion, preterm delivery and HELLP 
syndrome as 10.2, 30.5, 18.5, 10.7, 31.4 and 12.4%,  re-
spectively in 55,860 pregnant women with HDs.
Zibaeenezhad et al. (7) found a prevalence of 2.32% for 
HDs in pregnant women in south of Iran including a preva-
lence of 2.13% for chronic hypertension. Moreover, Khos-
ravi et al. (8) reported a prevalence of 9.8% for HDs among 
pregnant women who were admitted to a tertiary center in 
Tehran for delivery. So, the disease is also prevalent in Iran.
Infertility is also a common condition and physicians 
are deeply concerned about it, because it involves a cou-
ple, rather than a single individual. It is defined as inabil-
ity of a couple to conceive after one year of regular inter-
course without using any form of contraception (9).
The prevalence of infertility is markedly high in East-
ern Europe, North Africa, Oceania and sub Saharan Af-
rica (10). The main causes of infertility include male fac-
tors, decreased ovarian reserve, ovulatory factors, tubal 
factors, uterine factors, pelvic factors, and unexplained 
reasons (11). 
Once the pathologic basis of infertility is recognized, 
therapy is directed toward curing reversible causes and 
modifying irreversible etiologies. Therapeutic interven-
tions for both male and female infertility includes drug 
therapy (12) and surgery (13), with or without procedures 
like intra uterine insemination (IUI) or in vitro fertiliza-
tion (IVF) (14, 15). 
Methodology
We searched PubMed and Google search engines for 
incidence of hypertension and also history of infertility in 
pregnant women. We also checked the internet for causes 
of female infertility and their association with hyperten-
sion, all kinds of treatments and medications that are ap-
plied for female infertility and the chance and the mecha-
nisms by which they changing blood pressure (BP). Then 
we quested for general considerations, treatment modali-
ties and follow-up in pregnant cases with HDs, with or 
without a history of infertility.
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Physiological blood pressure changes during pregnancy 
Normotensive women usually experience about 5 to 10 
mmHg fall in their BP starting from the first trimester 
which may be continued up to the third trimester; after 
that, BP is restored to its preconception level (16). This 
is due to marked vasodilation which can overcome the 
increment of blood volume in this period. This phenome-
non can also induce normal BP in cases with mild chronic 
hypertension which results in reduction in dose or discon-
tinuation of antihypertensive medications or even mask-
ing previously undiagnosed cases.
Diagnosis and risk of hypertension
Hypertension is generally labeled when systolic BP is 
≥140 mmHg and/or diastolic BP is ≥90 mmHg, according 
to the mean of at least two measurements, checked using 
the same arm with at least fifteen minutes intervals, in 
clinic or in hospital (17). Although the definition of HDs 
is somewhat different in some references and defined only 
when diastolic BP is greater than 90 mmHg on two ses-
sions with more than 4 hours interval or when a single 
diastolic BP >110 mmHg was recorded (18). BP should 
be measured in the sitting position while the arm is at the 
level of the heart, using a cuff of appropriate size. Mild 
hypertension is defined as a diastolic BP of 90-99 mmHg 
and/ or a systolic BP of 140-149 mmHg.  Severe hyper-
tension is defined as a systolic BP of ≥160 mmHg or a 
diastolic BP of ≥110 mmHg. Obviously, moderate hyper-
tension ranges between mild and moderate values (Table 
1) (17, 19, 20).
Table 1: Grading of severity of hypertension and the need for antihyper-
tensive treatment
Grade of 
hypertension
Blood pressure 
levels (mm Hg)
Treat Grade of treatment
Mild Diastolic: 90-99 
Systolic: 140-149
No* Not applicable*
Moderate Diastolic: 100-109
Systolic: 150-159
Yes <150 systolic* 
<100 diastolic*
Severe 
hypertension
Diastolic: ≥110 
Systolic: ≥160
Yes <150 systolic*
<100 diastolic*
*; Except for women with chronic hypertension with end-organ damage who should be 
treated even if blood pressure is mild and the goal is to normalizing their blood pressure. 
Modified from: hypertension in pregnancy: the NICE guidelines (20).
HDs are classified into four major groups according 
to working group of National Institutes of Health (NIH) 
report on high BP in pregnancy (3): i. Chronic or pre-
existing hypertension diagnosed either before pregnancy 
or earlier than 20 gestational weeks, ii. Preeclampsia-
eclampsia. Preeclampsia described as the presence of 
hypertension, along with new-onset of significant pro-
teinuria of >0.3 g/24 hours. However, there are some 
other definitions in other references which are more pre-
cise and complete, iii. Preeclampsia superimposed on 
chronic hypertension, and iv. Gestational hypertension 
is defined as a hypertension beginning at later than 20 
gestational weeks and can persist for up to 42 days post-
partum.
It has also been mentioned that gestational hypertension 
usually resolves within up to 12 weeks post-partum how-
ever this is not applicable for cases with chronic hyperten-
sion (21).
Risk factors for chronic hypertension are: early middle 
age or about age 45, black race, using tobacco, too much 
salt (sodium) in diet, too little potassium, calcium or vi-
tamin D in diet, drinking too much alcohol, high levels 
of stress, being overweight or obese, little or no exercise, 
history of high BP in the family (22). Certain chronic con-
ditions also may increase the risk of high BP, such as kid-
ney disease, diabetes and sleep apnea.
Risk factors for preeclampsia include: prior history of 
preeclampsia, family history of preeclampsia, intervals of 
more than 10 years between pregnancies, nulliparity, pre-
existing medical conditions like antiphospholipid syndrome, 
type 1 or 2 diabetes mellitus, chronic kidney disease, chronic 
hypertension, chronic autoimmune diseases like systemic 
lupus erythematous (SLE), mother age more than 40 years, 
BMI >35 kg/m2,  multiple pregnancy, high BP in the first vis-
it, gestational trophoblastic disease, fetal triploidy  (23, 24).
Thus, infertility by itself is neither a major risk fac-
tor for HDs during pregnancy nor a major risk factor for 
preeclampsia.
Hypertension and infertility
Higher rates of HDs in women who underwent infertil-
ity treatment might be due to higher age and/or increased 
risk of multiple pregnancies. Also, pathologic basis of in-
fertility like polycystic ovaries and endometriosis, must 
be considered as a cause of or in correlation with hyper-
tension. In these conditions, hypertension may simply oc-
cur due to associated obesity or insulin resistance, andro-
gen excess, sympathetic nerve over activity and chronic 
use of oral contraceptives (25, 26).
Furthermore, chronic hypertension can cause poor egg 
quality; also, many hypertensive women suffer from obe-
sity which is mostly a result of excessive estrogen pro-
duction which can lead to infertility. Antihypertensive 
medications like angiotensin receptor inhibitors (ARBs) 
and calcium channel blockers typically affect male fertil-
ity rather than female ones.
The most common medications which are used for 
treatment of female infertility are clomiphene, met-
formin, aromatase inhibitors like letrozole, human cho-
rionic gonadotropins (hCG) like menotropin, dopamine 
agonists like bromocriptine and gonadotropin-releasing 
hormone (GnRH) agonists like leuprolide which is used 
in GnRH protocol and consists of progesterone and es-
tradiol. Among these, letrozole, leuprolide and estradiol 
can induce hypertension with a prevalence rate of 5-8% 
(27-29), 8% (30) and 3-7% (31), respectively. Although 
bromocriptine usually causes vasodilatation and special-
ly edema thereafter, there are some case reports on bro-
mocriptine-induced hypertension (32). 
Hypertension and Infertility
Int J Fertil Steril, Vol 12, No 2, Jul-Sep 2018              94
It is well known that estrogen-containing medications 
can induce hypertension in premenopausal women, but 
the mechanisms are not fully understood. Supraphysi-
ologic concentrations of estrogen and its effect on incre-
ment of angiotensinogen and insulin-like growth factor 
I production by liver, increased sympathetic activity and 
increased expression of angiotensin subtype 1 (AT1) re-
ceptor in the kidneys, are the possible mechanisms (33).
In recently published meta-analysis, it was shown that 
metformin decreases BP specially systolic type, particu-
larly in nondiabetic cases (34).
Farland et al. (35) reported relative risk of hyperten-
sion in infertile women receiving different kinds of treat-
ments, as follows: clomiphene: relative risk (RR)=0.97, 
confidence interval (CI): 0.90-1.04; gonadotropin alone: 
RR=0.97, CI: 0.87-1.08, IUI: RR=0.86, CI: 0.71-1.03, 
IVF: RR=0.86, CI: 0.73-1.01. 
We could not find any correlation between risk of hy-
pertension and hCG administration after adjustment by 
higher chance of multiple pregnancy and other prevalent 
factors.
In a meta- analytic study which was done in Germa-
ny, oocyte donation was also reported as a risk factor for 
HDs in pregnancy and this effect was possibly mediated 
through immunological processes and ovarian dysfunc-
tion (36).
In 1994, Sealey et al. (37) revealed that renin and uri-
nary aldosterone excretion had 5-fold increases during 
the luteal phase (day 7) in patients who underwent ovar-
ian stimulation. Alternatively, Tollan et al. (38) showed a 
statistically significant decrement in both systolic and di-
astolic BP during ovarian stimulation for IVF, most prob-
ably due to decreased level of adrenalin.
In a retrospective observational cohort, Hernández-Díaz 
et al. (39) interviewed 5151 women within six months of 
delivery and stated that the incidence of gestational hyper-
tension was significantly greater in women with a history 
of infertility who were treated for this problem (15.8%) 
than among those infertile cases who did not receive such 
managements (8.9%). Results were the same for patients 
with preeclampsia and also after adjustment for age, twin 
pregnancy, parity and body mass index. There were some 
cases without a history of infertility treatments who men-
tioned some difficulties in fertility in past or untreated 
sub-fertility in the present pregnancy. Surprisingly, these 
women were not at increased risk of hypertension and this 
finding demonstrates the direct role of infertility treatment 
in induction of hypertension. All kinds of infertility treat-
ment approaches or drugs were associated with a simi-
lar increased risk, although not unexpectedly, treatments 
with the greatest chance of multiple gestations, were as-
sociated with higher risk of HDs.
Alternatively, in a prospective cohort study, Farland 
et al. (35) included 116,430 women and followed them 
for 20 years to assess the risk of development of hy-
pertension in later life. Among them, 12,183 received 
some kinds of infertility treatment. During follow-up, 
approximately 20,066 women were diagnosed with hy-
pertension. The authors emphasized that only infertility 
due to tubal causes was accompanied by greater risk of 
hypertension as these cases had 15% greater risk of hy-
pertension than women without a history of infertility. 
But among other causes of infertility, no clear relation 
was detected between receiving fertility treatment and 
subsequent hypertension. 
Meanwhile, Toshimitsu et al. (40) showed that the in-
cidence of HDs was significantly higher in infertile cou-
ples with IVF/intracytoplasmic sperm injection concep-
tion than the spontaneous conception group in both the 
women aged ≥40 years (20.5 vs. 7.9%) and those aged 
30-34 years (14.3 vs. 2.6%). However, gestational diabe-
tes mellitus, premature birth, or low birth weight were not 
different between these two groups.
So, it seems that we should be concerned about hyper-
tension in all pregnancies particularly in women under-
went infertility treatments. 
General considerations 
BP measurement should be performed in all routine pre-
natal visits and more frequently in high risk patients. Ac-
cording to the last version of guideline of prenatal care, 
pregnant women should be visited every 4 weeks up to 
week 28, every 2 weeks thereafter until week 36 and then 
weekly up to time of delivery (41). If HDs were diag-
nosed, then BP should be checked weekly in milder forms 
and no association with preeclampsia, or twice and four 
times a week in moderate and severe forms, respectively 
(24). 
Low salt diet is not advised, and consumption of calci-
um or magnesium supplements, fish oil derivatives, vita-
mins, antioxidants and garlic are also ineffective. No data 
supports using heparin and nitric oxide (18, 42). Weight 
reduction is not recommended. Moderate activity is sug-
gested for patients with well-controlled chronic hyperten-
sion and it seems that there is no increase in incidence of 
preeclampsia in this group. If preeclampsia occurs, some 
physical activity restrictions may be required although it 
does not change maternal or fetal outcome (43). Bedtime 
low-dose aspirin (75-100 mg/day) should be started and 
continued until delivery to prevent preeclampsia although 
it has neutral effect on perinatal and maternal morbidity 
(17, 44). No evidence supports administration of dipy-
ridamole (18).
Drug therapy
In the first half of pregnancy, selected patients with pre-
existing hypertension may need to discontinue their anti-
hypertensive medications due to physiological drop in BP 
during this period, however, close monitoring is mandatory. 
New-onset hypertension during pregnancy is an indication 
for assessing proteinuria for early diagnosis of preeclamp-
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sia and should be repeated weekly. Fetal growth should be 
regularly monitored by ultrasonography (24). 
Most of the patients with pre-existing hypertension 
have mild-to-moderate increment in BP, thus physicians 
are not much worried about cardiovascular complications 
in this group. There are still scanty evidence about clinical 
benefits of administration of drugs to subjects with mild 
hypertension during pregnancy (Table 1) (45). Sometimes 
these patients should be hospitalized for at least a short 
period of time for confirmation of diagnosis and risk strat-
ification specially for ruling out or ruling in preeclampsia 
for which the only effective treatment is termination of 
pregnancy.
Last European Society of Hypertension/ European So-
ciety of Cardiology (ESH/ESC) guidelines approved a 
systolic BP of 140 mmHg or a diastolic BP of 90 mmHg 
as the thresholds for antihypertensive treatment in preg-
nant women with one of the following criteria:  gestation-
al hypertension (with or without proteinuria), pre-existing 
hypertension superimposed by gestational hypertension, 
symptomatic hypertension and subclinical hypertension 
associated with end-organ damage.
The ESH/ESC thresholds are a systolic BP of 150 
mmHg and a diastolic BP of 95 mmHg in any other con-
ditions (Table 2) (43, 46).
Unfortunately, none of the antihypertensive agents 
could significantly reduce perinatal mortality (45). 
Continuation of current medication except for angi-
otensin-converting enzyme (ACE) inhibitors, ARBs, 
and direct renin inhibitors may be the best strategy in 
cases with pre-existing hypertension. Drug of choice is 
α-Methyldopa and labetalol shows comparable effica-
cy. Calcium channel blockers like nifedipine are drugs 
of second choice (17, 47). Dosages are stated in Table 
3. Generally, diuretics should be avoided in all kinds 
of HDs as they may theoretically decrease placental 
blood flow (46); however, thiazides are mentioned as 
the second line therapy in some references (43, 48) as 
their teratogenicity or adverse effects have not been ex-
tensively studied (45). Mineralocorticoid receptor an-
tagonists should never be prescribed (43). Nowadays, 
hydralazine  is used only in hypertensive urgencies in 
intravenous form, although its chronic oral use showed 
no adverse effect. Prazosin and atenolol are no more 
recommended during pregnancy (17).  
Table 3: Oral antihypertensive drugs commonly used in pregnancy
Drug Indication FDA category Initial dose Maximum dose Potential side effects
Methyldopa Often used as first line B 125-250 mg BD 500 mg QID Lethargy
Labetalol Often used as first line C 100 mg BD 200-400 mg QID Exacerbation of asthma
Nifedipine 
(immediate release)
Second line or 
alternative first line
C 10-20 mg BD 40 mg BD Concern for synergy with magnesium 
sulfate for neuromuscular depression
Modified from: Queensland Clinical Guideline: Hypertensive disorders of pregnancy (23) and Chronic Hypertension in Pregnancy (16). Category B; Animal reproduction studies have 
failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women, Category C; Animal reproduction studies have shown an adverse effect 
on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks, BD; Twice 
a day, and QID; Four times a day. 
Table 2: Recommendations for the management of hypertension
Recommendations Class of recommendation Level of evidence
Non-pharmacological management for pregnant women with systolic BP of 140-150 mmHg 
or diastolic BP of 90-99 mmHg is recommended.
I C
In women with gestational hypertension or pre-existing hypertension superimposed by ges-
tational hypertension or with hypertension and subclinical organ damage or symptoms at 
any time during pregnancy, initiation of drug treatment is recommended at a BP of 140/90 
mmHg. In any other circumstances, initiation of drug treatment is recommended if SBP 
≥150 mmHg or DBP ≥95 mmHg.
I C
Systolic BP ≥170 mmHg or diastolic BP ≥110 mmHg in a pregnant woman is an emergency, 
and hospitalization is recommended.
I C
Induction of delivery is recommended in gestational hypertension with proteinuria with 
adverse conditions such as visual disturbances, coagulation abnormalities, or fetal distress
I C
In preeclampsia associated with pulmonary edema, nitroglycerine given as an intravenous 
infusion, is recommended.
I C
In severe hypertension, drug treatment with intravenous labetalol or oral methyldopa or 
nifedipine is recommended.
I C
Women with pre-existing hypertension should be considered to continue their current medi-
cation except for ACE inhibitors, ARBs, and direct renin inhibitors under close BP-moni-
toring
IIa C
From: ESC Guidelines on the management of cardiovascular diseases during pregnancy (46). 
BP; Blood pressure, SBP; Systolic blood pressure, DBP; Diastolic blood pressure, ACE; Angiotensin converting enzyme, and ARB; Angiotensin receptor blocker.
Hypertension and Infertility
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Severe hypertension is defined as BP ≥160/110 mmHg 
or systolic BP ≥170 mmHg and diastolic BP ≥110 
mmHg. It is a medical emergency which requires hospi-
tal admission, rapid management and monitoring every 
10 to 20 minutes depending on management strategy. In 
a systematic review of cases with very high BP, pub-
lished from Cochrane library in 2013, 15 different an-
tihypertensive medications in 35 trials were compared 
and the results showed that less persistent hypertension 
was seen with calcium channel blockers than with hy-
dralazine and they also had less side effects compared to 
labetalol (50). The most popular plan is to start treatment 
with intravenous labetalol or oral nifedipine as soon as 
possible (Table 4) (49). Intravenous hydralazine is not 
the first choice according to some references (46) while 
there are references suggesting it as medication of first 
choice (48, 49). The optimal drug in hypertensive crises 
can be sodium nitroprusside. Intravenous magnesium 
sulfate is the preferable drug only for management of 
seizures and/or preventing eclampsia in selective cases 
of severe preeclampsia (46). If recurrent seizures oc-
curred, alternative anticonvulsants like benzodiazepines, 
such as lorazepam and diazepam, phenytoin (Dilantin), 
and levetiracetam can be started (51). 
Table 4: Management of severe hypertension during pregnancy
Type of medication Strategy
Hydralazine (IV) 5 mg IV bolus, then 10 mg every 20-30 min-
utes to a maximum of 25 mg, repeat in several 
hours as necessary
Labetalol (IV) 20 mg IV bolus over 2 minutes, then 40 mg 
10 minutes later, 80 mg every 10 minutes for 
two additional doses to a maximum of 220 
mg
Nifedipine
(oral) (controversial)
10 mg po, repeat every 20 minutes to a maxi-
mum of 30 mg 
Sodium nitroprusside
(rarely used, usually 
when others fail)
0.25 µg/kg/minutes to a maximum of 5 µg/
kg/minutes IV infusion Fetal cyanide poison-
ing may occur if used for more than 4 hours
Modified from: The Seventh Report of the Joint National Committee on Prevention, Detec-
tion, Evaluation, and Treatment of High Blood Pressure and Emergent therapy for acute-
onset, severe hypertension during pregnancy and the postpartum period. Committee 
Opinion No. 623. American College of Obstetricians and Gynecologists (48, 49).
Blood pressure goals in pregnancy
As a general agreement, diastolic BP should be kept 
above 80 mmHg (19). The American College of Obstet-
rics and Gynecology (ACOG) recommended to maintain 
BP between 120/80 and 160/105 mm Hg in pregnant 
women with HDs with no complications (52). Clinical 
practice guidelines of the Society of Obstetricians and 
Gynecologists of Canada emphasize that systolic BP 
of 130-155 mmHg and diastolic BP of 80-105 mmHg 
should be achieved in patients without any comorbidities 
and systolic BP of 130-139 mmHg and diastolic pressure 
of 80-89 mmHg are the goal BPs in cases with comor-
bidities like diabetes mellitus (53). According to a recent 
systematic review of patients with non -severe hyperten-
sion, target BP is variable and obviously dependent on the 
type of HDs in pregnancy and presence or absence of co-
morbidities (1). So, if any form of end-organ dysfunction 
like left ventricular hypertrophy, chronic kidney disease 
and hypertensive retinopathy exists, the target BP would 
be 140/90 mmHg (5, 17, 20). In cases with no end-organ 
damages, target BP would be different. Accordingly in 
any form of HDs, the target is BP of 150/80-100 mmHg 
(5, 20), 130-159/80-105 mmHg (17), or, 160/110 mmHg, 
in patients with chronic hypertension, it would be120-
159/80-104 mmHg and at last in women with gestational 
hypertension or non-severe preeclampsia, the goal of BP 
is defined as 160/110 mmHg (54). 
Time and mode of delivery
Uncontrolled severe hypertension is the most common 
maternal reason for preterm childbirth. There are no defi-
nite data for time of termination of pregnancy in patients 
with chronic hypertension specially when BP is well con-
trolled. Delivery at term is suggested for cases with gesta-
tional hypertension. Patients with milder forms of preec-
lampsia can be observed up to gestational week 37 (17). 
Although the amount of proteinuria is not an important 
factor (43), severe preeclampsia and eclampsia neces-
sitate urgent termination of pregnancy. Some cases with 
severe preeclampsia at low gestational age, can be closely 
observed for up to 34 weeks of pregnancy for better prog-
nosis for child (23). In a recent study, adverse perinatal 
outcome of postponing delivery to later than 39 weeks 
of gestation (55) was shown; probably the best time for 
delivery in gestational hypertension is between weeks 38 
and 39 (56).
Rout of delivery should be determined as obstetric indi-
cation, so vaginal delivery is the first choice (43). If vagi-
nal delivery is planned, then active managing of the third 
stage of labor with oxytocin is recommended (17).
Breast feeding
Although all antihypertensive medications are secreted 
in milk at very low levels, breast feeding is safe in hyper-
tensive mothers. Lower dosages of captopril and enalapril 
are harmless. No adverse effect following administration 
of calcium channel blockers has been seen, although there 
are some controversies about nifedipine. Some references 
also recommend not to use amlodipine. Diuretics are best 
avoided as they potentially decrease milk production. 
Beta blockers other than atenolol can be used safely (16, 
17, 23, 24, 43).
Methyldopa should not be used in this period due to 
some reports about the risk of post-natal depression (23), 
so must be discontinued within 2 days postpartum if has 
been prescribed during pregnancy (19, 24).
Short and long-term cardiovascular complications 
BP commonly rises immediately over the first 5 days af-
ter delivery (18.5% in a recent report) (57). Patients with 
HDs during pregnancy may become normotensive after 
labor but then becomes hypertensive in the first week. 
Women with a history of HDs during pregnancy, par-
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ticularly when associated with early-onset pre-eclampsia, 
premature labor before 32 weeks of gestation, stillbirth, 
or IUGR are at high risk for developing cardiovascular 
complications such as hypertension, stroke and ischemic 
heart disease in later life. So, lifestyle modifications and 
close screening for sign and symptoms of cardiovascular 
diseases and also early detection of other risk factors are 
highly suggested in these groups. Notably, risk of subse-
quent hypertension or prehypertension in previously nor-
motensive women with a history of HDs in pregnancy, is 
higher than others regardless of coincidence with gesta-
tional diabetes, even during the first year postpartum (58).
Recurrence risk in a subsequent pregnancy
In a subsequent pregnancy, mothers who experienced 
hypertension in their first pregnancy are at greater risk 
specially if it was early onset or associated with HELLP 
syndrome. Although some other predictors like pre-preg-
nancy plasma volume have been suggested for risk as-
sessment (59), they are not clinically relevant (60).
Conclusion
HDs of pregnancy are highly prevalent, so do infertility 
treatments. It seems that elevated BP is somehow more 
common in women who received infertility treatments. 
Since hypertension is associated with many short and also 
long-term comorbidities and even perinatal mortality, this 
group of patients should be particularly screened, treated 
and followed up for high BP, although the hypertension 
treatment is not markedly different from those given to 
fertile mothers.  
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